Ebola Virus: Symptoms, Transmission, Treatment and Prevention

Possible exposure and symptoms: call for help promptly

What is Ebola virus, and why does the species matter?

Ebola disease is the broader name for illness caused by certain viruses in the genus Orthoebolavirus. More precisely, Ebola virus belongs to the species Orthoebolavirus zairense, previously called Zaire ebolavirus, and causes Ebola virus disease. Sudan virus and Bundibugyo virus cause related Ebola diseases, and Taï Forest virus can also cause human illness. You may see older names in research papers, product labels or news reports. These naming differences are medically important: a headline about an “Ebola vaccine” may refer only to protection against Ebola virus, rather than Sudan or Bundibugyo virus. Ask which virus is involved whenever a vaccine, medicine or outbreak announcement is discussed. A shared disease-family name does not establish that the same intervention works for all members. [4]

Ebola is not inevitably fatal. However, it can be life-threatening, and a mild-looking start cannot predict the eventual course. WHO reports that case fatality in past outbreaks has ranged from about 25% to 90%. Those historical figures describe groups of reported patients, not an individual person’s chance of survival. They should not be used to decide whether seeking treatment is worthwhile. Early care is important throughout the disease, including when the responsible virus has no approved specific treatment. [1]

How Ebola spreads, and what does not count as ordinary transmission

Blood, body fluids and contaminated items

Person-to-person transmission occurs when infectious blood or other body fluids enter through broken skin or the moist surfaces of the eyes, nose or mouth. Relevant fluids can include vomit, diarrhea, urine, saliva, sweat, breast milk and amniotic fluid from a person who is sick with Ebola. Contact with contaminated clothing, bedding, needles or medical equipment can also create an exposure. A person with acute Ebola disease becomes infectious when symptoms begin, rather than during the symptom-free incubation period. Recovery requires a separate discussion because virus can persist in some body sites, including semen, after the acute illness. That specific survivor-related risk does not mean every interaction with a survivor is dangerous. There is no evidence that mosquitoes or other insects spread Ebola viruses. [5]

Ebola is not spread through the air in the same way as a respiratory infection. Simply being nearby, passing someone in a public place, or sitting beside a person is different from contact with infectious body fluids or contaminated materials. This distinction should reassure people about ordinary encounters without minimizing the risk during unprotected hands-on care. A splash of bodily fluid, handling soiled bedding, or touching an infected body after death is a different situation and needs professional assessment. Risk depends on what actually happened, not only on distance or whether you recognized the person as ill. The severity of an outbreak also depends on the virus involved, the circumstances of transmission and access to medical care. [6]

Animal-to-human exposure

Ebola viruses can enter the human population through contact with the blood, organs or other body fluids of infected animals. Fruit bats are believed to be a natural reservoir, while infected non-human primates and some other wild animals have been linked to human cases. Primates can become severely ill themselves; they should not be assumed to be healthy carriers that are safe to handle. In affected settings, avoid handling sick or dead wildlife and do not investigate an unusual animal death yourself. Report concerns through local authorities. A broad animal association is not a reason to fear every animal or blame an entire community. The relevant concern is exposure to potentially infected animals and their fluids. [7]

Ebola symptoms and the 2–21-day incubation period

Symptoms generally start between 2 and 21 days after infection; CDC describes an average of about 8 to 10 days. The earliest illness may resemble many ordinary infections, with fever, marked tiredness, muscle or joint pain, headache, sore throat and reduced appetite. Vomiting, diarrhea and abdominal pain may follow. A rash or other symptoms can develop too. These features cannot diagnose Ebola on their own. A person with malaria, influenza, typhoid or another infection may have similar symptoms, so the combination of illness and a relevant exposure history matters. If public-health staff are monitoring you, report new symptoms as instructed instead of waiting for a full list to appear. Do not treat an average incubation time as a deadline after which you can stop the agreed monitoring. [8]

Bleeding is not present in every patient and may occur later, so its absence does not rule out Ebola. Severe vomiting and diarrhea can cause major fluid loss, and some patients develop shock or failure of multiple organs. Other concerning developments include shortness of breath, confusion or seizures. The disease does not follow an identical schedule in everyone, and a person should not wait for a particular “stage” before seeking assessment. Symptoms may progress over several days, while recovery can also take time. Descriptions of early “dry” and later “wet” symptoms are clinical shorthand, not a home checklist that can establish when someone is safe. [9]

What happens after a possible exposure?

Contact the health team even if you feel well

If you have had direct contact with someone suspected or confirmed to have Ebola, contact a healthcare provider or local public-health service for advice even if you currently feel well. Explain the date, the type of contact and whether body fluids were involved. The team decides whether you meet its definition of a contact and what follow-up is needed. WHO describes monitoring contacts for 21 days after exposure, with regular checks and immediate reporting of symptoms. Be accurate about dates and tell the team if another possible exposure occurs, since the relevant follow-up period depends on the exposure history. Discuss travel plans with the health authority first. Feeling well is useful information, but it is not a substitute for an agreed follow-up plan. [10]

Isolation and quarantine have different purposes. Isolation separates someone who may have an infectious illness from others while assessment or treatment takes place. Quarantine concerns someone who has been exposed but is not yet ill. Restrictions depend on the exposure category and the responsible jurisdiction; not every traveler receives identical instructions. In U.S. guidance, high-risk exposures can lead to quarantine, daily monitoring and restrictions on commercial travel during the incubation period. Public-health teams determine clearance and any necessary transport arrangements. Ask for clear instructions about work, school, visitors and travel, and who to call if symptoms appear. Do not independently decide that a reassuring moment or an informal test result ends the restrictions you have been given. [11]

Why contact tracers ask detailed questions

Contact tracing identifies people who may have been exposed, explains what that means and follows their health so any illness can be recognized quickly. Staff may ask about activities, caregiving, work, visits and other people present after the patient became ill. Being named as a contact does not mean you have Ebola, and cooperating is not an admission that you caused an outbreak. Give the team the most accurate information you can, including uncertainty rather than a guessed answer. Ask how follow-up will happen and how to reach the team between checks. If communication, language, work or caregiving responsibilities make the plan difficult, raise that early so practical arrangements can be discussed. The purpose is timely care and interruption of transmission. [12]

How clinicians assess and diagnose Ebola

Assessment begins with both the illness and the exposure history. Clinicians need the places and dates of travel, when symptoms began, and whether you cared for someone who was ill, attended a funeral, handled contaminated objects or worked with relevant laboratory materials. Exact activities often tell them more than a country name alone. Keep a simple timeline ready if you can, but do not delay the call to prepare paperwork. Screening questions guide a professional decision about precautions and testing; they are not a diagnosis you should apply to yourself. If Ebola is suspected, trained staff coordinate with infection-control specialists and public-health authorities. That coordination also helps arrange the right facility and prevent avoidable exposure during the assessment. [13]

Other illnesses still need prompt attention. CDC advises healthcare teams not to delay assessment, routine laboratory tests or appropriate treatment for more likely conditions while Ebola is being considered. Malaria is a particularly important alternative in an ill traveler from an area where it occurs. A careful team can investigate more than one possibility while following the required precautions. Tell clinicians about medicines already taken, other diagnoses and relevant travel prevention, rather than assuming that every symptom must have one explanation. The possibility of Ebola should lead to safer, coordinated care, not abandonment of ordinary medical needs. Likewise, a suspected alternative diagnosis is something for the clinical team to evaluate, rather than a reason to ignore a credible exposure. [14]

Laboratory confirmation is important because symptoms overlap and treatment options may depend on which virus is present. Testing is arranged by clinicians and public-health teams using appropriate laboratory services. Samples from a person with suspected Ebola require specialized safety measures. Do not collect, package, store, transport or send your own blood or other body fluids, and do not ask a friend to take a sample to a laboratory. The healthcare team should explain what is being tested and how results will be communicated. If further assessment is needed, follow its instructions about remaining separated from others. An online symptom checker, a photograph of a rash or a home experiment cannot replace this process. [15]

Ebola treatment: supportive care is essential

Supportive care means actively treating the effects of the infection while the body recovers. It is important for every form of Ebola disease, including infections for which there is no approved virus-specific medicine. Depending on the person’s condition, a clinical team may replace lost fluids and electrolytes, support blood pressure and oxygen levels, control pain, provide nutrition and treat other infections or complications. This is monitored medical care, not simply an instruction to drink more water at home. Vomiting, severe diarrhea, shock and organ problems can make needs change quickly. The route and amount of fluid, medicines and level of monitoring must be chosen for the individual patient. Early supportive care improves outcomes and should not wait for access to an experimental drug. [16]

Comfort and communication are also part of treatment. Tell the clinical team about pain, nausea, difficulty drinking and other symptoms rather than assuming they are unavoidable. Staff working in protective equipment face practical challenges, including reduced dexterity and difficulty seeing, but relief of pain and other symptoms remains a core part of care. Patients and families can ask how symptoms are being assessed and when to alert the team to a change. Follow the team’s plan instead of adding remedies or trying to administer fluids or injections independently. The need for infection-control precautions does not remove the patient’s need for comfort, explanation and attentive nursing. [18]

Medicines are specific to the responsible virus

For laboratory-confirmed Ebola virus disease caused by Ebola virus, formerly called Zaire ebolavirus, WHO recommends the monoclonal antibody medicines ansuvimab, sold as Ebanga, or the antibody combination sold as Inmazeb. They are used alongside optimized supportive care. These recommendations arose from clinical trials and apply to that specific virus, rather than every disease called Ebola. Treatment should be arranged promptly by the specialist team after diagnosis. Access can differ between locations, so an approval does not guarantee that a particular facility has a medicine immediately available. Ask the team which virus has been identified, which treatments are appropriate and whether transfer or referral is needed. This discussion should occur while supportive care continues. [17]

There are no FDA-approved specific treatments for Sudan, Bundibugyo or Taï Forest virus disease. Specialist teams may discuss appropriately governed research, but an investigational product should not be described as a proven cure. Continue to seek medical care: the absence of an approved targeted medicine does not mean that supportive treatment has no value. [16]

Be cautious about sellers claiming that supplements, herbal mixtures or products bought online can prevent or cure Ebola. FDA warns that fraudulent claims often appear during outbreaks and states that approved Ebola treatments are not available for purchase on the internet. A professional-looking website, a personal testimonial or a promise to “boost immunity” is not evidence of effectiveness. Do not self-medicate or postpone urgent assessment while trying a marketed remedy. Tell the care team about any product you have already taken, including its packaging or ingredient list if available without delaying help. Even a real medical product approved for one Ebola virus species cannot simply be assumed to work against another species. [21]

Ebola vaccines: established protection and important limits

In the United States, FDA licenses Ervebo for prevention of disease caused by Zaire ebolavirus in people aged 12 months and older. The age in a product’s approval describes who falls within its indication; it does not mean that every person above that age should routinely receive it. Whether vaccination is appropriate depends on the exposure setting and the responsible vaccination program. When reviewing information, check the current product indication rather than relying on an old announcement of the original approval. Some older material still refers only to adults. Ask the vaccination team which product is being offered, what infection it is intended to prevent and what recommendations apply to your situation. [22]

Ervebo is a live recombinant vaccine, but it does not contain the complete Ebola virus and cannot give someone Ebola virus disease. That does not remove the need for medical screening before vaccination. Clinicians consider contraindications, precautions and individual circumstances, and recipients still need to follow infection-prevention measures after vaccination. Protective equipment, safe work practices and exposure reporting continue to matter for healthcare staff and responders. Vaccination should never be treated as permission to handle body fluids or take an avoidable risk. If you become unwell after a possible exposure, report the symptoms and your vaccination history to the assessing team. A vaccination record is useful clinical information, rather than a reason to dismiss symptoms without assessment. [23]

WHO’s Ebola vaccine questions and answers, updated on 9 September 2026, identify Ervebo as the licensed, WHO-prequalified vaccine currently available specifically for Ebola virus disease caused by Ebola virus. They state that there are no licensed vaccines for the other disease-causing species. For Ebola virus disease, WHO recommends Ervebo in outbreak response and for preventive vaccination of healthcare and frontline workers in areas at risk of future outbreaks. Older pages may describe a different number of vaccines or previous programs, so dates and the named virus matter. Public-health teams decide the strategy and eligibility for a particular response. A report that vaccination is happening somewhere does not, by itself, establish which disease it is proven to prevent. [24]

Why vaccine research does not equal established protection

WHO’s emergency guidance dated 31 August 2026 addresses research on using Ervebo during Bundibugyo virus disease outbreaks. Although animal and other evidence suggested possible cross-protection, WHO concluded that available evidence was insufficient to determine whether it provides clinically meaningful protection against Bundibugyo disease in people. The guidance recommends research protocols to generate that evidence while established outbreak-control measures continue. For a person offered vaccination in that setting, an important question is whether it is being provided for established Ebola virus protection or within research evaluating a different virus. Ask what is known, what remains uncertain and what follow-up is required. Participation or receipt of a vaccine must not be presented as proof of protection that has not yet been demonstrated. [25]

The current Ervebo label notes that vaccination may not protect everyone and that the duration of protection is unknown. A history of a severe allergic reaction to a vaccine component must be discussed before vaccination, and the team should know about immune-suppressing conditions or treatment. It can then weigh risks and benefits for the person’s situation. Pain at the injection site, headache, feverishness, tiredness and muscle or joint symptoms are among reported reactions; serious allergic reactions require immediate medical attention. Ask how to report a reaction and what symptoms need urgent assessment. Do not assume that a fever after vaccination is necessarily a harmless side effect when an Ebola exposure is also possible. Let the clinical or public-health team assess the circumstances. [26]

Prevention at home, in healthcare and during funerals

Do not try to create a treatment unit at home

Safe Ebola care relies on several coordinated protections: early assessment, appropriate separation of a potentially infectious patient, trained personnel and facility-specific infection-control procedures. A mask or a pair of gloves by itself is not a complete plan for caring for someone with suspected Ebola. If you are worried about a family member, contact health services and follow their instructions while care is arranged. Do not improvise a cleanup of vomit, blood or other contaminated material, and do not handle soiled belongings to prepare for the person’s arrival at hospital. Tell the responding team what is present so trained professionals can manage it safely. These precautions are meant to make care possible while protecting the household and responders. [27]

Hospitals may limit visits or physical contact while a person is being evaluated or treated. CDC guidance allows facilities to consider exceptions for someone essential to a patient’s wellbeing, but such visits require assessment, instruction and controlled arrangements. Relatives should ask the facility how to stay in touch and how information can be shared with a chosen family contact. Do not enter an isolation area or bring items into it without permission. If you previously cared for the patient, tell staff about that contact before visiting so your own risk can be assessed. Restricted access can be distressing, particularly for children or someone who needs communication support; raise those needs with the care team rather than trying to bypass precautions. [28]

Safe and dignified funerals

A person who has died from Ebola can still transmit infection through bodily fluids, and contaminated belongings may also be hazardous. Families should alert health authorities and wait for the trained team rather than washing, touching, moving or preparing the body themselves. Safe burial should also be dignified. WHO emphasizes involving families and religious or community leaders in planning respectful alternatives to practices that involve direct contact. Tell the team which customs, prayers, witnesses or ways of marking the grave are important to the family, and ask what can be arranged safely. Clear explanations and compassionate treatment matter throughout this process. Preventing infection should be accompanied by support for grief and respect for the person who has died. [29]

Pregnancy, breastfeeding and newborn care

Pregnancy requires coordinated obstetric and infectious-disease care when Ebola is suspected or confirmed. CDC does not identify evidence that pregnancy itself makes a person more likely to acquire Ebola virus infection, but infection during pregnancy can cause serious complications, including fetal loss and pregnancy-related bleeding. Decisions about labor, delivery and treatment must consider the pregnant patient, the baby and the safety of the healthcare team. Tell the assessing service about pregnancy or a recent birth during the first call, including if pregnancy is only possible. Do not delay care because of fear that every treatment will harm the baby. The specialist team should explain available options, uncertainties and the plan for both patients in language the family can understand. [31]

Babies born to someone with suspected or confirmed Ebola need specialist care and an individualized feeding plan. CDC advises that a patient being evaluated for Ebola should not breastfeed until the illness status is resolved, and that newborns of patients with confirmed Ebola should not breastfeed. The team must arrange appropriate nutrition and explain whether testing can guide safe resumption. Do not independently handle, share or transport expressed milk from a patient under evaluation. Tell clinicians promptly that a baby needs feeding support; avoiding an exposure should not mean leaving the infant without a safe nutrition plan. Discharge decisions for an exposed or infected newborn involve the clinical team and public-health authorities. These precautions should be explained sensitively and without blaming a parent. [32]

Recovery and respectful care for Ebola survivors

Survival does not always mean an immediate return to previous health. Some people experience fatigue, joint or muscle pain, headaches, memory or hearing problems, sleep difficulties, anxiety or depression. Virus may persist in particular body sites after acute recovery, but detection of viral genetic material is not the same as proving that every body fluid contains infectious virus. Routine healthcare must not be withheld from survivors. A new fever needs assessment for common infections as well as possible relapse, and new eye or neurological symptoms need professional attention. Tell the clinician about the previous Ebola illness so assessment and any special precautions can be planned appropriately. Do not assume every new symptom is caused by Ebola, but do not dismiss a significant change simply because the person was discharged. [33]

Arrange follow-up that addresses practical and emotional needs as well as physical symptoms. WHO’s survivor-care guidance describes comprehensive medical and psychosocial support, counselling and planning for continued care. Before discharge or at the next visit, ask who will coordinate appointments, how to obtain medicines and what changes should trigger an urgent call. Discuss fatigue that interferes with work, difficulties concentrating, distressing memories or worries about relationships. A relative can help keep an appointment list or accompany the person if the survivor wants that support. Recovery may require several types of care rather than one final test. The survivor should remain involved in decisions, including who receives information about their health and which support feels useful. [34]

Eye care deserves particular attention. Inflammation after Ebola can affect sight, and WHO has highlighted the importance of identifying and treating eye problems early to prevent serious consequences. Report new blurred vision or other eye changes promptly rather than waiting for a routine follow-up date. Ask the survivor-care team how to reach an eye specialist if symptoms occur, especially where services are difficult to access. Do not use someone else’s eye drops or assume that an eye problem will improve simply with more rest. Follow-up can be necessary even after the acute infection has resolved. The reason to mention the Ebola history is to guide appropriate assessment and safe care, not to discourage clinicians from providing treatment. [38]

Sexual health and virus persistence

Ebola virus can persist in semen after recovery, so survivors and partners should receive confidential counselling about safer sex and the available testing program. WHO guidance advises abstaining from sex or using condoms correctly and consistently until semen testing has produced two negative results. The care team should explain the testing schedule and the advice to follow when testing is unavailable. Do not treat a negative blood test or the disappearance of symptoms as proof that semen has also cleared the virus. Avoid assuming a single universal deadline applies to every survivor: evidence, testing access and individual circumstances need to be considered. Partners should be able to ask questions without judgment, and advice should include access to condoms and practical support. [35]

WHO does not recommend isolating recovered patients whose blood has tested negative for the virus. Survivors, partners and families deserve dignity, compassion and support with returning to community life. Precautions for specific fluids or medical procedures should be explained clearly, rather than used to justify broad social exclusion. Ask the survivor-care team to clarify any uncertainty about ordinary contact or follow-up. [1]

Travel, outbreak work and keeping advice current

Healthcare, humanitarian and other outbreak-response work should be arranged through an organization with a clear safety plan. CDC recommends appropriate training, access to protective equipment, designated safety support and plans covering illness, exposure assessment and medical evacuation. Know whom to contact during deployment and after returning, and report potential exposures promptly. Preparation also includes routine and destination-specific health protection, since an Ebola response does not remove other travel risks. For example, advice about yellow fever prevention and travel planning concerns a different infection; its vaccine does not protect against Ebola. Review insurance and evacuation arrangements before departure rather than assuming that ordinary travel coverage will meet outbreak-related needs. Volunteers, students and paid staff all need a workable plan. [30]

For UK-resident workers, UKHSA’s Returning Workers Scheme helps organizations coordinate screening and monitoring after relevant deployments. Employers are asked to register in advance where possible and provide returning staff’s travel details before arrival. The scheme’s geographical scope is updated as the situation changes, so organizations should check its current instructions instead of copying a list from an old deployment. If this applies to you, ask your organization how it will communicate with the scheme and who is responsible for your follow-up. This is particularly important when work locations, return dates or routes change. Public-health coordination should be part of the deployment plan from the beginning, rather than an unexpected task after landing. [36]

Travel advice can change more quickly than a general health guide. Current outbreak notices may specify affected areas, entry requirements, screening, restrictions or post-arrival follow-up, and those details can differ between countries. Before departure and again before returning, read the dated guidance from the destination and your home country’s health authorities. Discuss recent exposures or illness before boarding any transport. An old article saying that a previous outbreak ended is not evidence that every current destination is unaffected, and a broad country label does not describe every traveler’s personal exposure. Keep your itinerary and relevant contact details available for assessment. Follow the instructions issued for your circumstances, including any requirements that continue after you feel well. [37]

Risk assessment should be based on symptoms, travel and actual exposure, rather than nationality or origin. Fear can lead people to avoid survivors, returning workers or entire communities even when that response does not reflect how Ebola spreads. Share reliable information, acknowledge concerns and ask health professionals to explain what is known and uncertain. Clear, respectful communication helps people seek care and cooperate with necessary precautions. It also protects the dignity of those affected, who should not have to choose between receiving help and facing blame. [3]